{
    "organizations": [],
    "uuid": "0f1476a338ab48334e4b2c824ca3622d56b25be7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kuros-biosciences-fy-loss-at-eur-1/brief-kuros-biosciences-fy-loss-at-eur-16-5-mln-idUSFWN1S7014",
    "ord_in_thread": 0,
    "title": "BRIEF-Kuros Biosciences FY Loss At EUR 16.5 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - KUROS BIOSCIENCES AG:\n* IN 2018, AIMS TO CAPITALIZE ON RESTRUCTURING AS IT EXECUTES ON ITS RENEWED FOCUS ON ORTHOBIOLOGICS\n* FY LOSS 16.484 MILLION EUR VERSUS LOSS 19.744 MILLION EUR YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-30T13:04:00.000+03:00",
    "crawled": "2018-05-01T20:18:57.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "kuros",
        "bioscience",
        "ag",
        "aim",
        "capitalize",
        "restructuring",
        "executes",
        "renewed",
        "focus",
        "orthobiologics",
        "fy",
        "loss",
        "million",
        "eur",
        "versus",
        "loss",
        "million",
        "eur",
        "year",
        "ago",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}